| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue, net | 3,083 | 2,979 | 2,214 | 3,108 |
| Cost of product revenue | 532 | 527 | 515 | 541 |
| Research and development | 3,658 | 3,265 | 3,730 | 4,043 |
| Sales and marketing | 1,997 | 2,467 | 2,493 | 2,010 |
| General and administrative | 4,134 | 4,727 | 4,897 | 3,776 |
| Total operating expenses | 10,321 | 10,986 | 11,635 | 10,370 |
| Gain (loss) on extinguishment of debt | - | -1,822 | - | - |
| Loss from operations | -7,238 | -8,007 | -9,421 | -7,262 |
| Changes in fair value of freestanding and hybrid financial instruments designated at fair value option | 2,310 | 1,068 | 1,343 | 3,089 |
| Interest income (expense) | 6 | -15 | -56 | -162 |
| Other income (expense) | -94 | 322 | 112 | 168 |
| Loss before income tax expense | -9,648 | -10,560 | -10,596 | -10,021 |
| Net loss before equity in net loss of joint venture | - | - | -10,596 | - |
| Net loss | -9,648 | -10,560 | -10,596 | -10,021 |
| Net loss per share, basic | -6.28 | -10.26 | -16.7 | -1.05 |
| Net loss per share, diluted | -6.28 | -10.26 | -16.7 | -1.05 |
| Weighted-average common stock outstanding, basic | 1,513,178 | 1,014,783 | 626,644 | 9,370,136 |
| Weighted-average common stock outstanding, diluted | 1,513,178 | 1,014,783 | 626,644 | 9,370,136 |
Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. (JAGX)